Premium
Progress report on phase I/II clinical trial of Ad‐OC‐TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University
Author(s) -
HINATA NOBUYUKI,
SHIRAKAWA TOSHIRO,
TERAO SHUJI,
GODA KAZUMASA,
TANAKA KAZUSHI,
YAMADA YUJI,
HARA ISAO,
KAMIDONO SADAO,
FUJISAWA MASATO,
GOTOH AKINOBU
Publication year - 2006
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2006.01418.x
Subject(s) - medicine , prostate cancer , clinical trial , oncology , phases of clinical research , cancer , prostate , gynecology , urology
There is no effective therapy for hormone‐refractory prostate cancer and a novel therapeutic modality, such as a gene therapy, should be actively pursued. Previously, Gardner and Chung conducted a phase I clinical trial of Ad‐OC‐TK (recombinant adenoviral vector containing osteocalcin promoter‐driven herpes simplex virus thymidine kinase gene) plus VAL (valacyclovir) for the treatment of hormone‐refractory prostate cancer at the University of Virginia. We report on our ongoing phase I/II clinical trial of Ad‐OC‐TK plus VAL for the treatment of advanced prostate cancer at the Kobe University Hospital, Japan.